Kaufempfehlung für Coronado Industries WKN 931788 - 500 Beiträge pro Seite

[derAuktionator]

Wednesday April 25, 10:01 am Eastern Time
Press Release
SOURCE: Donner Corp. International
Donner Corp. International Issues Speculative Buy Recommendation on Coronado Industries, Inc.
SANTA ANA, Calif., April 25 /PRNewswire/ -- Donner Corp. International, a broker/dealer specializing in investment banking, headquartered in Santa Ana, Ca., today issued a Speculative Buy Recommendation and initiated coverage on Coronado Industries, Inc. (OTC Bulletin Board: CDIK - news), Fountain Hills, Arizona. Coronado Industries has developed a patented, non-invasive treatment for glaucoma, which impacts an estimated 70 million people worldwide.

Glaucoma is a disease of the eye characterized by high pressure within the eye, hardening of the eyeball, and eventual partial or complete loss of vision. The two-minute, non-invasive treatment developed by Coronado has successfully lowered the intraocular pressure in 94 percent of the glaucoma patients treated with no adverse side effects reported.

``Coronado`s Pneumatic Trabeculoplasty (PNT) treatment system has received a CE mark from the European Commission, allowing it to be marketed throughout Europe,`` Donner said. ``Coronado is moving forward to conduct a clinical study in the U.S. to support its 510 (k) application to the U.S. Food and Drug Administration to allow marketing in America.``

``What Coronado will bring to the worldwide marketplace is a completely revolutionary way to treat glaucoma, reducing, and, in some cases eliminating, the need for any other method of treatment,`` Donner said. ``Its agreement with CIBA Vision, the eye care unit of Novartis (NYSE: NVS - news), a world leader in healthcare, with $17.2 million in sales in 2000, for exclusive global licensing and distribution rights to the PNT treatment, is a major step in bringing the treatment to people suffering from this debilitating disease.``

Donner said it is also impressed with Coronado`s management team, including Dr. Leo Bones, co-originator of the world-renowned Radial Keratotomy process, the laser surgical procedure used to decrease nearsightedness, who heads the Company`s FDA compliance division.

``We believe Coronado Industries is highly undervalued considering the success of its new glaucoma treatment system, the huge market for this treatment, and the seminal agreement with CIBA Vision/Novartis. These factors indicate to us that Coronado Industries is well-positioned for upward movement,`` Donner concluded.

Copies of the Donner report on Coronado Industries are available at www.donnercorp.com.

Donner Corp. International is a member of the National Association of Securities Dealers, CRD 37702. Any information or opinion provided in this report/release does not solicit or make an offer to buy or sell any securities or any options, futures or other derivatives related to such securities herein. DCI and its affiliates may trade for their own accounts in any securities of the issuer or in related securities. DCI or its affiliates, directors, officers and employees, may have a long or short position in securities of the issuer or related investments. DCI or its affiliates may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any entity mentioned in this report/release. This research report/release has been prepared for general circulation and is circulated for general information only. It does not have regard to the specific investment objective, financial situation, suitability and the particular need of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in this report/release and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities, if any, may fluctuate and that each security`s price or value may rise or fall substantially. Accordingly, investors may receive back less than originally invested. Past performance is not indicative of future performance. Copyright 2001 DCI. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader`s attention to the fact that DCI recently received 18,000 shares of CDIK common stock for payment of DCI`s $5,000 due diligence fee and DCI will receive $2,500 per month from Coronado for services provided payable in an equivalent amount of CDIK restricted common stock.


MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X18454270

[topgun]

CORONADO ist eine ganz serioese Unternehmung die auch in Frankfurt gelistet ist!!

Habe alles uebrprueft stimmt genau, habe mir auch die Seite von Donner Corp. angesehen. Ich habe 20,0000 gekauft!!

Chart sieht auch gut aus! Aufladen kann ich nur sagen und die Kuh fliegen lassen!!

[Stockfinder]

Diese Krankheit ist - sorry - ein riesen Wachstumsmarkt - aber das haben auch schon ganz andere erkannt. Die Gesellschaft scheint aber auf einem sehr guten Weg zu sein - ist aber leider ein Penny - also immer etwas für Hardcorezocker!

Z.B. ist die Muttergesellschaft von Lambda-Physik - die Coherent Inc. - ebenfalls in diesen Bereichen am Forschen und Entwickeln!

Coherent`s Selecta(R) 7000 Laser Receives FDA Clearance Providing a New Option For Treating Open Angle Glaucoma


SANTA CLARA, Calif., Apr 17, 2001 /PRNewswire via COMTEX/ -- Coherent, Inc.
(Nasdaq: COHR) announced today that the U.S. Food and Drug Administration (FDA)
has cleared its application to market the Selecta(R) 7000 Glaucoma Laser System.
The Selecta 7000 is specifically designed to perform Selective Laser
Trabeculoplasty (SLT), which incorporates a new patent protected technique for
the treatment of open angle glaucoma, the leading cause of preventable blindness
in Americans over the age of 40.

Open angle glaucoma is a progressive degenerative disease in which the optic
nerve is slowly destroyed. It affects more than 50 million people worldwide. If
left unchecked open angle glaucoma cases can result in total blindness. The only
accepted treatment for open angle glaucoma is to lower intraocular pressure.

SLT lowers intraocular pressure by using short pulses of low energy laser light
to target melanin containing cells in the trabecular meshwork which drains fluid
from the eye, resulting in increased fluid outflow. The selective technique is
much less traumatic to the eye than argon laser trabeculoplasty (ALT), the
current laser procedure. The limitations of ALT are primarily related to its
coagulative effect, which leads to scarring of the trabecular meshwork. SLT
retains the therapeutic benefit of laser treatment -- reduced intraocular
pressure, without the collateral thermal damage to non-melanin containing cells
and to the trabecular meshwork structure.

The treatment, performed in an ophthalmologist`s office, was devised by Mark
Latina, M.D. at Wellman Laboratories, Massachusetts General Hospital in Boston.
Coherent has acquired an exclusive license from the Massachusetts General
Hospital to commercialize SLT and market the relevant laser technology. Coherent
developed the Selecta 7000 specifically for SLT. According to Dr. Latina, "SLT
has the potential to change the standard of care for patients with open angle
glaucoma."

SLT is being performed today in many international markets using Coherent`s
Selecta 7000 Glaucoma Laser System, including Japan where it has been approved
by the Ministry of Health, Labor and Welfare for more than two years.

According to "Prevent Blindness America" and the National Eye Health Program it
is estimated that the U.S. government spends over $1.5 billion annually in terms
of social security benefits, lost income, tax revenues and health care
expenditures in its fight against glaucoma. Now there is a new glaucoma
treatment option that may provide economic benefits to the health care system
compared to conventional therapy.

In the next few weeks, Coherent Medical Group will be joining forces with ESC
Medical Systems, Ltd. (Nasdaq: ESCM), and thereafter the combined company will
change its name to Lumenis, derived from the lumen, the Latin for light.
Mr.Yacha Sutton, President and CEO of ESC Medical Systems, and the soon to be
formed Lumenis commented, "This innovative product benefits patients and our
customers alike. Anything that helps prevent blindness is especially gratifying.
We are excited about the vast array of products that Lumenis will soon be able
to offer worldwide to help treat this and other ophthalmic diseases as well as
products used for aesthetic and surgical applications."

Jim Taylor, Coherent Medical Group President, commented "Coherent is pleased to
be part of the original research team exploring the treatment of the leading
cause of preventable blindness affecting as many as 3 million Americans and more
than 50 million people worldwide. Additionally, Coherent will continue to
benefit from this type of innovation as the owner of approximately 16.5% of the
equity in Lumenis."

Coherent Medical Group is a world leader in the development of laser products
and services for ophthalmic, aesthetic, and surgical applications. Coherent
Medical Group will be exhibiting the Selecta 7000 Glaucoma Laser System the
American Society of Cataract and Refractive Surgery (ASCRS) in San Diego,
California April 28 through May 2, 2001. The company will also sponsor a
Physician Symposium on Selective Laser Trabeculoplasty with Mark Latina, M.D.,
the inventor of SLT, on Sunday April 29th. Please visit us at booth #2121 for a
product demonstration and to receive more information about the Selecta 7000 and
the SLT Physician Symposium.

[danielelsner]

Coronado Zulassung European Commission ERHALTEN!

"Coronado`s Pneumatic Trabeculoplasty (PNT) treatment system has received a CE
mark from the European Commission, allowing it to be marketed throughout
Europe," Donner said. "Coronado is moving forward to conduct a clinical study in
the U.S. to support its 510 (k) application to the U.S. Food and Drug
Administration to allow marketing in America."